18. September 2023
QuGen GmbH, founded by Thomas carell and Pascal Giehr, provides high-sensitive long read sequencing (PacBio), bisulfite-free sequencing of DNA methylation and mass spectrometry quantification of non-canonical nucleobases in DNA and RNA. This includes also sample preparation and data analysis. With this QuGen fulfills unmet needs in quantification and positional information of epigenetic nucleobases.
Dr Daniel Andergassen received an ERC Starting Grant for his research on the molecular causes of gender-specific differences in heart failure.
25. Oktober. 2023
September 2023
Prof Baer de Oliveira Mann received an ERC Starting Grant for her NTase Pro project.
On May 1, the Cluster for Nucleic Acid Therapeutics Munich (CNATM) started its work.
CNATM is an innovation network of science and industry, which is funded with five million euros annually by the federal government, the Free State of Bavaria and participating companies. The research network consists of scientists from the leading universities LMU and TUM. The universities of Regensburg and Würzburg, the Helmholtz Center Munich and 17 companies from the region around Munich are also involved. A total of 22 applications were awarded funding, marking the start of the Nucleic Acid Isar Valley.
The multilateral collaborations of CNATM are creating a network from which novel nucleic acid-based drugs and next-generation vaccines will be developed. Recent discoveries give rise to the hope that the ability to design nucleic acids in a highly specific and theoretically predictable way will open up completely new therapeutic approaches in medicine and thus help many people. There is no substance class that is better suited to personalized medicine than nucleic acids. The Future Cluster wants to help nucleic acid therapies achieve a breakthrough and thus make a contribution that makes sense: curing people and creating jobs in and around Munich.
We are very pleased, to be one of only 7 clusters4future in Germany and in Bavaria the only one of the second round of the competition.
Our thanks go to all members and partner companies who made this possible.
Die LMU Ausgründung Eisbach Bio GmbH wurde vom Handelsblatt als eine der Top 5 vielversprechenden Biotechunternehmen in Deutschland erwähnt. Sie wurden von führenden Wagniskapitalgebern besonders häufig genannt, wenn es um vielversprechende Projekte in frühen Forschungsphasen geht.
Die LMU Ausgründung Eisbach Bio GmbH hat einen Texas Therapeutics Company Award vom Cancer Prevention and Research Institute of Texas (CPRIT) erhalten. Dieser Zuschuss wird die klinische Entwicklung von EIS-12656 unterstützen, das auf anspruchsvolle Krebsarten mit homologen Rekombinationsdefekten (HRD) abzielt. Zuvor hatte die Eisbach Bio GmbH sich bereits im Juni 2024 4,5 Mio $ Fördermittel gesichert.
Victor Ambros and Gary Ruvkun have been awarded the 2024 Nobel Prize for their discovery of the first microRNA, lin-4, in C. elegans.
This is the second consecutive Nobel Prize for nucleic acids, following the 2023 Nobel Prize for Katalin Karikó and Drew Weissmann for their work on
mRNA technology. The development of nucleic acid-based therapeutics is the goal of the Cluster for Nucleic Acid Therapeutics Munich (CNATM).
In CNATM leading academic groups and 14 biotech companies are working together to achieve this goal. Several CNATM partners are focusing on microRNA-based therapeutics (rnatics GmbH, Secarna Pharmaceuticals GmbH, Engelhardt Group at the Institut for Pharmacology and Toxikology at TUM, Yildirim Group at the Helmholtz München).
Prof. Irmela Jeremias is a pediatrician at the Hauner Children’s Hospital of LMU and a scientist at Helmholtz München. For her research on new targets to fight leukemia, she received a Reinhart Koselleck grant from the German Research Foundation (DFG). This grant supports highly innovative and promising projects. Her project aims to „Identify new targeted cancer therapies using in vivo CRISPR/Cas9 dropout screens in PDX models“.